1 1 1 1 1 1 1 BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 0 0 no 0 10 0 1 0 0 0
Abhishek A, abhishek A Ab Abh Abhi BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 ,.;:.:./-- 10 10 0 1 1 1 0
ORIGINAL RESEARCH original O OR ORI ORIG BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 10 0 1 0 0 1
Risk-stratifiedmonitoringfor Risk-stratifiedmonitoringfor risk-stratifiedmonitoringfor R Ri Ris Risk BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 - 1 7 0 0 0 0 1
sulfasalazinetoxicity:prognosticmodel sulfasalazinetoxicity:prognosticmodel sulfasalazinetoxicity:prognosticmodel s su sul sulf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 : 1 10 0 0 0 0 1
developmentandvalidation developmentandvalidation developmentandvalidation d de dev deve BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 no 0 6 0 0 0 0 1
Abhishek Abhishek abhishek A Ab Abh Abhi BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 no 0 2 0 0 0 0 1
, 1 , , , , , BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 0 ,, 2 3 0 0 0 0 1
, 2 , , , , , BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 0 ,,, 3 3 0 0 0 0 1
Maarten W maarten M Ma Maa Maar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 ,,,,, 5 10 0 0 0 0 1
Matthew D matthew M Ma Mat Matt BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 0 ,, 2 6 0 0 0 0 1
To cite: to T To To To BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 1 :, 2 7 0 0 0 0 1
Grainge M, grainge G Gr Gra Grai BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 1 ,,. 3 8 0 0 0 0 1
Risk-stratified monitoring risk-stratified R Ri Ris Risk BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 1 - 1 9 0 0 0 0 1
for sulfasalazine for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 : 1 9 0 0 0 0 1
prognostic model prognostic p pr pro prog BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 1 no 0 9 0 0 0 0 1
and validation. and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 . 1 8 0 0 0 0 1
2024;10:e003980. doi:10.1136/ 2024;10:e003980. 2 20 202 2024 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 0 1 ;:.:./ 6 10 0 0 0 0 1
rmdopen-2023-003980 rmdopen-2023-003980 rmdopen-2023-003980 r rm rmd rmdo BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 0 1 -- 2 6 0 0 0 0 1
► Additional ► ► ► ► ► BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 1 no 0 7 0 0 0 0 1
material is material m ma mat mate BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 . 1 9 0 0 0 0 1
To view, to T To To To BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 1 , 1 9 0 0 0 0 1
online (https:// online o on onl onli BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 1 (://././ 8 10 0 0 0 0 1
rmdopen-2023-003980). rmdopen-2023-003980). rmdopen-2023-003980). r rm rmd rmdo BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 0 1 --). 4 5 0 0 0 0 1
GN and gn G GN GN GN BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 2 . 1 10 0 0 0 0 1
Received 6 received R Re Rec Rece BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 10 0 0 0 0 1
Accepted 30 accepted A Ac Acc Acce BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 10 0 0 0 0 1
For numbered for F Fo For For BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 10 0 1 0 0 1
end of end e en end end BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 . 1 5 0 1 0 0 1
Correspondence to correspondence C Co Cor Corr BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 8 0 1 0 0 1
Dr Abhishek dr D Dr Dr Dr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 2 ; 1 10 0 1 0 0 1
Abhishek. Abhishek@ abhishek. A Ab Abh Abhi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 2 .@ 2 9 0 1 0 0 1
nottingham. ac. nottingham. n no not nott BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 .. 2 8 0 1 0 0 1
Epidemiology Epidemiology epidemiology E Ep Epi Epid BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 10 0 1 0 0 0
© Author(s) © © © © © BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 2 ()( 3 8 0 0 0 0 1
employer(s)) 2024. employer(s)) e em emp empl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 ()).- 5 10 0 0 0 0 1
permitted under permitted p pe per perm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 . 1 8 0 0 0 0 1
Published by published P Pu Pub Publ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 . 1 6 0 0 0 0 1
ABSTRACT: ABSTRACT: abstract: A AB ABS ABST BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 : 1 10 0 0 0 0 1
Background Sulfasalazine-induced background B Ba Bac Back BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 -, 2 6 0 0 0 0 1
nephrotoxicity and nephrotoxicity n ne nep neph BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 no 0 8 0 0 0 0 1
long-term treatment. long-term l lo lon long BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 -. 2 7 0 0 0 0 1
3 monthly 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 0 2 no 0 8 0 0 0 0 1
long-term treatment long-term l lo lon long BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 - 1 8 0 0 0 0 1
monitoring after monitoring m mo mon moni BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 ., 2 8 0 0 0 0 1
developed and developed d de dev deve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 9 0 0 0 0 1
significant blood, significant s si sig sign BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 , 1 10 0 0 0 0 1
sulfasalazine treatment. sulfasalazine s su sul sulf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 . 1 3 0 0 0 0 1
Design Retrospective design D De Des Desi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 . 1 5 0 0 0 0 1
Setting UK setting S Se Set Sett BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 . 1 8 0 0 0 0 1
Research Datalink research R Re Res Rese BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 0 2 no 0 8 0 0 0 0 1
development and development d de dev deve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 2 . 1 5 0 0 0 0 1
Participants Age participants P Pa Par Part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 , 1 7 0 0 0 0 1
inflammatory condition inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 . 1 8 0 0 0 0 1
Study period study S St Stu Stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 . 1 7 0 0 0 0 1
Outcome Sulfasalazine outcome O Ou Out Outc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 8 0 0 0 0 1
monitoring blood-test monitoring m mo mon moni BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 -. 2 4 0 0 0 0 1
Analysis Patients analysis A An Ana Anal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 8 0 0 0 0 1
first primary first f fi fir firs BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 , 1 9 0 0 0 0 1
drug discontinuation, drug d dr dru drug BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 ,, 2 8 0 0 0 0 1
2019. Penalised 2019. 2 20 201 2019 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 0 2 . 1 8 0 0 0 0 1
the risk the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 . 1 8 0 0 0 0 1
predictor data. predictor p pr pre pred BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 . 1 8 0 0 0 0 1
of calibration of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 . 1 5 0 0 0 0 1
Results 8936 results R Re Res Resu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 0 2 no 0 7 0 0 0 0 1
development cohort development d de dev deve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 2 (,-) 4 8 0 0 0 0 1
and 5203 and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 8 0 0 0 0 1
cohort (280 cohort c co coh coho BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 (,-). 5 9 0 0 0 0 1
predictors were predictors p pr pre pred BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 . 1 8 0 0 0 0 1
D and d D D D D BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 2 no 0 0 0 0 0 0 1
Royston D royston R Ro Roy Roys BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 2 . 1 8 0 0 0 0 1
and 0.79, and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 .,.() 5 9 0 0 0 0 1
Royston D royston R Ro Roy Roys BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 2 (). 3 9 0 0 0 0 1
(0.96 to (0.96 ( (0 (0. (0.9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 2 (..).(..),. 11 8 0 0 0 0 1
Conclusion This conclusion C Co Con Conc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 8 0 0 0 0 1
toxicity uses toxicity t to tox toxi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 no 0 8 0 0 0 0 1
to risk-stratify to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 -- 2 9 0 0 0 0 1
sulfasalazine treatment. sulfasalazine s su sul sulf BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 . 1 3 0 0 0 0 1
INTRODUCTION INTRODUCTION introduction I IN INT INTR BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 7 no 0 2 0 1 0 0 1
Sulfasalazine is sulfasalazine S Su Sul Sulf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 7 - 1 10 0 1 0 0 1
ment of ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 7 - 1 9 0 1 0 0 1
matoid arthritis matoid m ma mat mato BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 7 (), 3 9 0 1 0 0 1
(PsA), axial (psa), ( (P (Ps (PsA BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 7 (),, 4 10 0 1 0 0 1
and infrequently and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 7 no 0 7 0 1 0 0 1
inflammatory bowel inflammatory i in inf infl BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 7 ()( 3 9 0 1 0 0 1
WHAT IS what W WH WHA WHAT BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 7 no 0 10 0 0 0 0 1
⇒ Hepatic, ⇒ ⇒ ⇒ ⇒ ⇒ BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 7 ,- 2 9 0 0 0 0 1
fasalazine occurs fasalazine f fa fas fasa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 7 no 0 8 0 0 0 0 1
months of months m mo mon mont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 7 . 1 3 0 0 0 0 1
⇒ Nevertheless, ⇒ ⇒ ⇒ ⇒ ⇒ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 7 ,- 2 9 0 0 0 0 1
ist societies, ist i is ist ist BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 7 ,, 2 9 0 0 0 0 1
Rheumatology recommend rheumatology R Rh Rhe Rheu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 7 no 0 8 0 0 0 0 1
at 3 at a at at at BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 7 . 1 9 0 0 0 0 1
⇒ Other ⇒ ⇒ ⇒ ⇒ ⇒ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 7 ,, 2 9 0 0 0 0 1
Society of society S So Soc Soci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 7 no 0 8 0 0 0 0 1
after the after a af aft afte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 7 . 1 6 0 0 0 0 1
⇒ It ⇒ ⇒ ⇒ ⇒ ⇒ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 7 , 1 9 0 0 0 0 1
renal toxicities renal r re ren rena BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 7 no 0 10 0 0 0 0 1
and monitoring and a an and and BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 7 -. 2 6 0 0 0 0 1
WHAT THIS what W WH WHA WHAT BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 9 no 0 10 0 0 0 0 1
⇒ This ⇒ ⇒ ⇒ ⇒ ⇒ BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 9 - 1 9 0 0 0 0 1
criminated patients criminated c cr cri crim BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 9 no 0 10 0 0 0 0 1
toxicity during toxicity t to tox toxi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 9 -. 2 6 0 0 0 0 1
⇒ It ⇒ ⇒ ⇒ ⇒ ⇒ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 9 no 0 10 0 0 0 0 1
independent validation independent i in ind inde BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 9 . 1 5 0 0 0 0 1
⇒ The ⇒ ⇒ ⇒ ⇒ ⇒ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 9 , 1 9 0 0 0 0 1
in people in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 9 - 1 10 0 0 0 0 1
matory conditions. matory m ma mat mato BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 9 . 1 3 0 0 0 0 1
⇒ Any ⇒ ⇒ ⇒ ⇒ ⇒ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 9 no 0 9 0 0 0 0 1
start of start s st sta star BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 9 -,, 3 9 0 0 0 0 1
diabetes, methotrexate diabetes, d di dia diab BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 9 ,, 2 9 0 0 0 0 1
prescription and prescription p pr pre pres BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 9 - 1 9 0 0 0 0 1
fasalazine toxicity. fasalazine f fa fas fasa BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 9 . 1 3 0 0 0 0 1
HOW THIS how H HO HOW HOW BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 10 , 1 10 0 0 0 0 1
PRACTICE OR practice P PR PRA PRAC BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 10 no 0 5 0 0 0 0 1
⇒ This ⇒ ⇒ ⇒ ⇒ ⇒ BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 1 10 no 0 9 0 0 0 0 1
easily ascertained easily e ea eas easi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 10 . 1 7 0 0 0 0 1
⇒ It ⇒ ⇒ ⇒ ⇒ ⇒ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 1 10 no 0 9 0 0 0 0 1
between monitoring between b be bet betw BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 10 . 1 5 0 0 0 0 1
⇒ The ⇒ ⇒ ⇒ ⇒ ⇒ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 1 10 no 0 10 0 0 0 0 1
national and national n na nat nati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 10 no 0 9 0 0 0 0 1
writing groups writing w wr wri writ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 10 - 1 9 0 0 0 0 1
term sulfasalazine term t te ter term BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 10 . 1 5 0 0 0 0 1
RMD Open: rmd R RM RMD RMD BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 11 :./--.://... 12 10 0 0 0 0 0
Protected by protected P Pr Pro Prot BLOCKSTART PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 11 ,,,. 4 10 0 0 1 1 0
2 2 2 2 2 2 2 BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 1 0 no 0 10 0 1 0 0 0
Abhishek A, abhishek A Ab Abh Abhi BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 ,.;:.:./-- 10 10 0 1 1 0 0
RMD Open rmd R RM RMD RMD BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 no 0 10 0 1 0 0 0
RMD Open rmd R RM RMD RMD BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 no 0 10 0 1 0 0 0
RMD Open rmd R RM RMD RMD BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 no 0 10 0 1 0 0 0
is mostly is i is is is BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 9 0 0 0 0 1
safety profile). safety s sa saf safe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ).-, 4 9 0 0 0 0 1
cause cytopenia cause c ca cau caus BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
the first the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -,- 3 8 0 0 0 0 1
toxicity is toxicity t to tox toxi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 .-- 3 10 0 0 0 0 1
alluria and alluria a al all allu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 , 1 9 0 0 0 0 1
in those in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 0 . 1 8 0 0 0 0 1
is recommended is i is is is BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -- 2 8 0 0 0 0 1
impairment. 17 impairment. i im imp impa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 . 1 2 0 0 0 0 1
There is there T Th The Ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 8 0 0 0 0 1
how to how h ho how how BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -- 2 9 0 0 0 0 1
ment for ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 ,/ 2 8 0 0 0 0 1
toxicity. The toxicity. t to tox toxi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 .() 3 8 0 0 0 0 1
guidelines recommend guidelines g gu gui guid BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 8 0 0 0 0 1
blood count blood b bl blo bloo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 (),(),- 7 9 0 0 0 0 1
trolytes and trolytes t tr tro trol BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 () 2 9 0 0 0 0 1
treatment followed treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
and no and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 . 1 9 0 0 0 0 1
the contrary, the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 , 1 8 0 0 0 0 1
(ACR) guidelines (acr) ( (A (AC (ACR BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 () 2 8 0 0 0 0 1
first 3 first f fi fir firs BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 , 1 9 0 0 0 0 1
testing for testing t te tes test BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 0 ,- 2 8 0 0 0 0 1
tion of tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 .- 2 9 0 0 0 0 1
tics for tics t ti tic tics BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 , 1 8 0 0 0 0 1
LFT and lft L LF LFT LFT BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 - 1 8 0 0 0 0 1
treatment. 20 treatment. t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ., 2 8 0 0 0 0 1
monitoring schedule monitoring m mo mon moni BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 8 0 0 0 0 1
treatment, or treatment, t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ,- 2 9 0 0 0 0 1
during long-term during d du dur duri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -. 2 6 0 0 0 0 1
To predict to T To To To BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 8 0 0 0 0 1
ities during ities i it iti itie BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
inform the inform i in inf info BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 , 1 8 0 0 0 0 1
validated a validated v va val vali BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
myelotoxicity, hepatotoxicity myelotoxicity, m my mye myel BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 ,/ 2 9 0 0 0 0 1
to sulfasalazine. to t to to to BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 . 1 2 0 0 0 0 1
METHODS METHODS methods M ME MET METH BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 1 3 no 0 1 0 0 0 0 1
Data source data D Da Dat Data BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 3 no 0 2 0 0 0 0 1
Data from data D Da Dat Data BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 3 no 0 8 0 0 0 0 1
(CPRD) Aurum (cprd) ( (C (CP (CPR BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 3 ()- 3 8 0 0 0 0 1
opment and opment o op opm opme BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 3 ,. 2 9 0 0 0 0 1
anonymised longitudinal anonymised a an ano anon BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 3 no 0 9 0 0 0 0 1
records originated records r re rec reco BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 3 no 0 9 0 0 0 0 1
Health Service health H He Hea Heal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 1 3 . 1 9 0 0 0 0 1
of UK of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 , 1 9 0 0 0 0 1
CPRD are cprd C CP CPR CPRD BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 3 . 1 8 0 0 0 0 1
CPRD includes cprd C CP CPR CPRD BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 3 , 1 8 0 0 0 0 1
lifestyle factors lifestyle l li lif life BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 (,,),, 6 10 0 0 0 0 1
results of results r re res resu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 3 - 1 10 0 0 0 0 1
tions. CPRD tions. t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 3 . 1 8 0 0 0 0 1
terms of terms t te ter term BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 no 0 9 0 0 0 0 1
different software different d di dif diff BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 .- 2 9 0 0 0 0 1
tices that tices t ti tic tice BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 3 no 0 9 0 0 0 0 1
identifiable using identifiable i id ide iden BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 3 . 1 9 0 0 0 0 1
Study design study S St Stu Stud BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 5 no 0 4 0 1 0 0 1
Retrospective cohort retrospective R Re Ret Retr BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 5 . 1 10 0 1 0 0 1
Study period study S St Stu Stud BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 5 no 0 3 0 1 0 0 1
1 January 1 1 1 1 1 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 1 5 . 1 10 0 1 0 0 1
Study population study S St Stu Stud BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 5 no 0 2 0 0 0 0 1
Participants aged participants P Pa Par Part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 5 no 0 9 0 0 0 0 1
of inflammatory of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 (,,, 4 9 0 0 0 0 1
PsA and psa P Ps PsA PsA BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 5 ) 1 8 0 0 0 0 1
general practitioner general g ge gen gene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 (). 3 9 0 0 0 0 1
Patients were patients P Pa Pat Pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 5 -- 2 9 0 0 0 0 1
tration in tration t tr tra trat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 5 - 1 9 0 0 0 0 1
fied as fied f fi fie fied BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 5 ., 2 9 0 0 0 0 1
were required were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 no 0 9 0 0 0 0 1
prescription either prescription p pr pre pres BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 no 0 10 0 0 0 0 1
disease in disease d di dis dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 . 1 9 0 0 0 0 1
90-day period 90-day 9 90 90- 90-d BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 5 - 1 9 0 0 0 0 1
may lag may m ma may may BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 1 0 0 1 5 .- 2 8 0 0 0 0 1
mised the mised m mi mis mise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 5 - 1 9 0 0 0 0 1
treatment appearing treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 no 0 9 0 0 0 0 1
they moved they t th the they BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 . 1 9 0 0 0 0 1
chronic liver chronic c ch chr chro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 , 1 9 0 0 0 0 1
kidney disease kidney k ki kid kidn BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 () 2 9 0 0 0 0 1
were excluded were w we wer were BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 . 1 9 0 0 0 0 1
Sulfasalazine prescriptions sulfasalazine S Su Sul Sulf BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 7 no 0 4 0 0 0 0 1
In the in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 2 7 , 1 9 0 0 0 0 1
occur in occur o oc occ occu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 . 1 9 0 0 0 0 1
prescriptions are prescriptions p pr pre pres BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 . 1 10 0 0 0 0 1
also organise also a al als also BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 no 0 8 0 0 0 0 1
abnormalities. Once abnormalities. a ab abn abno BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 ., 2 10 0 0 0 0 1
typically approximately typically t ty typ typi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 - 1 10 0 0 0 0 1
ment, the ment, m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 7 ,, 2 9 0 0 0 0 1
including with including i in inc incl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 no 0 8 0 0 0 0 1
patients' GP patients' p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 7 '() 3 9 0 0 0 0 1
shared-care protocols. shared-care s sh sha shar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 -.-, 4 9 0 0 0 0 1
the GP the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 no 0 9 0 0 0 0 1
are side are a ar are are BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 -, 2 9 0 0 0 0 1
and treatment and a an and and BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 7 . 1 9 0 0 0 0 1
Start of start S St Sta Star BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 9 - 1 3 0 0 0 0 1
Patients were patients P Pa Pat Pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 9 no 0 9 0 0 0 0 1
primary care primary p pr pri prim BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 no 0 10 0 0 0 0 1
of outcome, of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 ,,,- 4 8 0 0 0 0 1
prescription gap, prescription p pr pre pres BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 ,, 2 9 0 0 0 0 1
December 2019 december D De Dec Dece BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 1 0 0 2 9 . 1 4 0 0 0 0 1
Outcome Outcome outcome O Ou Out Outc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 9 no 0 1 0 0 0 0 1
Sulfasalazine toxicity-associated sulfasalazine S Su Sul Sulf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 9 - 1 9 0 0 0 0 1
the outcome the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 .- 2 9 0 0 0 0 1
tion gap tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 9 - 1 9 0 0 0 0 1
result or result r re res resu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 - 1 9 0 0 0 0 1
within ±60 within w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 . 1 10 0 0 0 0 1
tests were tests t te tes test BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 no 0 9 0 0 0 0 1
were present: were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 :./,- 5 9 0 0 0 0 1
phil count phil p ph phi phil BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 2 9 ./,/, 5 9 0 0 0 0 1
alanine transaminase alanine a al ala alan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 9 ()/- 4 8 0 0 0 0 1
nase (AST) nase n na nas nase BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 9 ()/, 4 9 0 0 0 0 1
defined as defined d de def defi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 no 0 9 0 0 0 0 1
codes recorded codes c co cod code BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 / 1 8 0 0 0 0 1
creatinine concentration, creatinine c cr cre crea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 9 , 1 9 0 0 0 0 1
RMD Open: rmd R RM RMD RMD BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 11 :./--.://... 12 10 0 0 0 0 1
Protected by protected P Pr Pro Prot BLOCKSTART PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 11 ,,,. 4 10 0 0 1 0 1
3 3 3 3 3 3 3 BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 2 0 no 0 10 0 1 0 0 0
Abhishek A, abhishek A Ab Abh Abhi BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 ,.;:.:./-- 10 10 0 1 1 0 0
Epidemiology Epidemiology epidemiology E Ep Epi Epid BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 10 0 1 0 0 0
of acute of o of of of BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 ().- 4 10 0 0 0 0 1
tion study tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 ,. 2 9 0 0 0 0 1
of abnormal of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 - 1 9 0 0 0 0 1
potentially explained potentially p po pot pote BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 . 1 8 0 0 0 0 1
A random a A A A A BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 2 0 no 0 8 0 0 0 0 1
with abnormal with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 -. 2 10 0 0 0 0 1
diagnostic codes diagnostic d di dia diag BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 - 1 9 0 0 0 0 1
tions within tions t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 no 0 9 0 0 0 0 1
were extracted. were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 .( 2 9 0 0 0 0 1
expertise) screened expertise) e ex exp expe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 ) 1 9 0 0 0 0 1
could potentially could c co cou coul BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 - 1 9 0 0 0 0 1
tion or tion t ti tio tion BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 . 1 4 0 0 0 0 1
Predictors Predictors predictors P Pr Pre Pred BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 1 no 0 1 0 0 0 0 1
These were these T Th The Thes BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 1 no 0 9 0 0 0 0 1
team based team t te tea team BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 no 0 8 0 0 0 0 1
of the of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 .,, 3 9 0 0 0 0 1
(BMI), alcohol (bmi), ( (B (BM (BMI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 1 (), 3 8 0 0 0 0 1
they associate they t th the they BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 -(). 4 9 0 0 0 0 1
Individual inflammatory individual I In Ind Indi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 1 - 1 8 0 0 0 0 1
rately because rately r ra rat rate BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 1 no 0 10 0 0 0 0 1
common in common c co com comm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 . 1 8 0 0 0 0 1
CKD stage ckd C CK CKD CKD BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 1 no 0 8 0 0 0 0 1
clearance. 29 clearance. c cl cle clea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 .,, 3 8 0 0 0 0 1
paracetamol were paracetamol p pa par para BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 1 no 0 8 0 0 0 0 1
with sulfasalazine with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 no 0 9 0 0 0 0 1
Formulary. Methotrexate, formulary. F Fo For Form BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 1 .,, 3 8 0 0 0 0 1
were included were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 , 1 9 0 0 0 0 1
enzymes and enzymes e en enz enzy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 .( 2 8 0 0 0 0 1
<2×10 9 <2×10 < <2 <2× <2×1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 1 /,/ 3 9 0 0 0 0 1
count <150×10 count c co cou coun BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 /)(/ 4 9 0 0 0 0 1
or AST or o or or or BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 /) 2 8 0 0 0 0 1
care prescription care c ca car care BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 - 1 9 0 0 0 0 1
penia and/or penia p pe pen peni BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 1 /. 2 8 0 0 0 0 1
The latest the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 1 , 1 9 0 0 0 0 1
diseases recorded diseases d di dis dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 - 1 10 0 0 0 0 1
and latest and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 no 0 8 0 0 0 0 1
prior to prior p pr pri prio BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 -- 2 9 0 0 0 0 1
tors except tors t to tor tors BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 1 no 0 9 0 0 0 0 1
GP records gp G GP GP GP BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 1 / 1 9 0 0 0 0 1
30-59 mL/min. 30-59 3 30 30- 30-5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 1 -/.- 4 8 0 0 0 0 1
term conditions term t te ter term BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 .-- 3 9 0 0 0 0 1
used to used u us use used BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 no 0 9 0 0 0 0 1
did not did d di did did BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 -. 2 6 0 0 0 0 1
Patient and patient P Pa Pat Pati BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 5 0 0 0 0 1
Patient and patient P Pa Pat Pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 9 0 0 0 0 1
in selecting in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 3 4 . 1 10 0 0 0 0 1
advised to advised a ad adv advi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 9 0 0 0 0 1
rather than rather r ra rat rath BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 - 1 8 0 0 0 0 1
clinical trial. clinical c cl cli clin BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 . 1 2 0 0 0 0 1
Sample size sample S Sa Sam Samp BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 3 5 no 0 2 0 1 0 0 1
In a in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 3 5 no 0 9 0 1 0 0 1
RA, 85 ra, R RA RA, RA, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 5 ,,- 3 9 0 1 0 0 1
bocytopenia or bocytopenia b bo boc bocy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 no 0 9 0 1 0 0 1
follow-up of follow-up f fo fol foll BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 -.. 3 10 0 1 0 0 1
of treatment of o of of of BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 , 1 9 0 1 0 0 1
the minimum the t th the the BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 no 0 8 0 0 0 0 1
overfitting (a overfitting o ov ove over BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 (.) 3 9 0 0 0 0 1
precise estimation precise p pr pre prec BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 no 0 9 0 0 0 0 1
(113 outcomes) (113 ( (1 (11 (113 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 5 ()- 3 7 0 0 0 0 1
ters, Cox-Snell ters, t te ter ters BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 ,-.,./ 6 9 0 0 0 0 1
person-year, 16 person-year, p pe per pers BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 -,-- 4 10 0 0 0 0 1
period of period p pe per peri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 .. 2 10 0 0 0 0 1
The sample the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 5 no 0 9 0 0 0 0 1
larger than larger l la lar larg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 no 0 8 0 0 0 0 1
size of size s si siz size BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 . 1 3 0 0 0 0 1
Statistical analysis statistical S St Sta Stat BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 6 no 0 3 0 0 0 0 1
Multiple imputation multiple M Mu Mul Mult BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 6 , 1 8 0 0 0 0 1
alcohol intake alcohol a al alc alco BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 no 0 9 0 0 0 0 1
equations. 34 equations. e eq equ equa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 .- 2 10 0 0 0 0 1
opment dataset opment o op opm opme BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 - 1 9 0 0 0 0 1
set-a pragmatic set-a s se set set- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 - 1 9 0 0 0 0 1
of CPRD of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 . 1 8 0 0 0 0 1
candidate predictors, candidate c ca can cand BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 ,- 2 9 0 0 0 0 1
function and function f fu fun func BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 . 1 9 0 0 0 0 1
undertaken using undertaken u un und unde BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 '' 2 9 0 0 0 0 1
combined dataset combined c co com comb BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 . 1 8 0 0 0 0 1
Model development model M Mo Mod Mode BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 7 no 0 2 0 0 0 0 1
Fraction polynomial fraction F Fr Fra Frac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 7 (-)- 4 7 0 0 0 0 1
ysis was ysis y ys ysi ysis BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 7 - 1 8 0 0 0 0 1
with continuous with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 , 1 8 0 0 0 0 1
than the than t th tha than BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 (.), 4 7 0 0 0 0 1
transformed. All transformed. t tr tra tran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 .(- 3 7 0 0 0 0 1
eters) were eters) e et ete eter BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 7 )- 2 7 0 0 0 0 1
cients of cients c ci cie cien BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 7 no 0 7 0 0 0 0 1
using Rubin's using u us usi usin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 '. 2 8 0 0 0 0 1
risk equation risk r ri ris risk BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 ' 1 8 0 0 0 0 1
sulfasalazine discontinuation sulfasalazine s su sul sulf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 7 - 1 7 0 0 0 0 1
test results test t te tes test BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 - 1 8 0 0 0 0 1
development data. development d de dev deve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 3 7 . 1 8 0 0 0 0 1
t=5 years, t=5 t t= t=5 t=5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 7 ,-- 3 8 0 0 0 0 1
tion when tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 7 , 1 8 0 0 0 0 1
is equivalent is i is is is BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 --- 3 8 0 0 0 0 1
mate, was mate, m ma mat mate BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 ,- 2 8 0 0 0 0 1
sion coefficients sion s si sio sion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 7 ()' 3 8 0 0 0 0 1
values (X). values v va val valu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 (). 3 8 0 0 0 0 1
absolute risk absolute a ab abs abso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 : 1 4 0 0 0 0 1
Predicted risk predicted P Pr Pre Pred BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 7 no 0 8 0 0 0 0 1
discontinuation at discontinuation d di dis disc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 7 -()(),() 8 10 0 0 0 0 1
is the is i is is is BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 - 1 8 0 0 0 0 1
and βX and a an and and BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 7 ,. 2 10 0 0 0 0 1
Model internal model M Mo Mod Mode BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 10 no 0 7 0 0 0 0 1
The performance the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 10 - 1 9 0 0 0 0 1
tion (where tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 10 (.)- 4 9 0 0 0 0 1
ting agreement ting t ti tin ting BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 3 10 no 0 8 0 0 0 0 1
outcomes. Internal outcomes. o ou out outc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 . 1 8 0 0 0 0 1
correct performance correct c co cor corr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 no 0 9 0 0 0 0 1
overfitting by overfitting o ov ove over BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 10 no 0 10 0 0 0 0 1
samples of samples s sa sam samp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 3 10 . 1 9 0 0 0 0 1
was fitted was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 no 0 9 0 0 0 0 1
performance was performance p pe per perf BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 no 0 9 0 0 0 0 1
RMD Open: rmd R RM RMD RMD BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 11 :./--.://... 12 10 0 0 0 0 0
Protected by protected P Pr Pro Prot BLOCKSTART PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 11 ,,,. 4 10 0 0 1 0 0
4 4 4 4 4 4 4 BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 0 no 0 10 0 1 0 0 0
Abhishek A, abhishek A Ab Abh Abhi BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 ,.;:.:./-- 10 10 0 1 1 0 0
RMD Open rmd R RM RMD RMD BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 no 0 10 0 1 0 0 0
RMD Open rmd R RM RMD RMD BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 no 0 10 0 1 0 0 0
RMD Open rmd R RM RMD RMD BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 no 0 10 0 1 0 0 0
(apparent performance) (apparent ( (a (ap (app BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 ()( 3 9 0 0 0 0 1
model performance), model m mo mod mode BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 ), 2 8 0 0 0 0 1
(difference in (difference ( (d (di (dif BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 (- 2 9 0 0 0 0 1
mance). A mance). m ma man manc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 ). 2 9 0 0 0 0 1
the average the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 9 0 0 0 0 1
samples. This samples. s sa sam samp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 . 1 10 0 0 0 0 1
datasets, and datasets, d da dat data BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 , 1 9 0 0 0 0 1
by averaging by b by by by BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 10 0 0 0 0 1
from each from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 .- 2 9 0 0 0 0 1
of performance of o of of of BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 no 0 8 0 0 0 0 1
calculated, as calculated, c ca cal calc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 , 1 8 0 0 0 0 1
minus the minus m mi min minu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 . 1 3 0 0 0 0 1
To account to T To To To BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 2 - 1 8 0 0 0 0 1
ment process, ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 2 ,-- 3 9 0 0 0 0 1
plied by plied p pl pli plie BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 no 0 9 0 0 0 0 1
baseline hazards baseline b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 2 - 1 8 0 0 0 0 1
shrunken β-coefficients shrunken s sh shr shru BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 -- 2 10 0 0 0 0 1
tion was tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 2 ,. 2 9 0 0 0 0 1
D statistic, d D D D D BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 3 2 ,, 2 9 0 0 0 0 1
as a as a as as as BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 2 , 1 9 0 0 0 0 1
Table 1 table T Ta Tab Tabl BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 3 no 0 10 0 0 0 0 1
Predictor* Predictor* predictor* P Pr Pre Pred BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 3 * 1 10 0 0 0 0 1
Development cohort development D De Dev Deve BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 4 3 () 2 10 0 0 0 0 1
N=8936 N=8936 n=8936 N N= N=8 N=89 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 3 no 0 2 0 0 0 0 1
Validation cohort validation V Va Val Vali BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 3 () 2 10 0 0 0 0 1
N=5203 N=5203 n=5203 N N= N=5 N=52 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 3 no 0 2 0 0 0 0 1
Age, mean age, A Ag Age Age, BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 4 ,() 3 10 0 0 0 0 1
55.3 (14.8) 55.3 5 55 55. 55.3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 4 .(.) 4 6 0 0 0 0 1
55.5 (14.8) 55.5 5 55 55. 55.5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 4 .(.) 4 6 0 0 0 0 1
Female sex female F Fe Fem Fema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 4 no 0 5 0 0 0 0 1
5535 (61.9) 5535 5 55 553 5535 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 4 (.) 3 6 0 0 0 0 1
3240 (62.3) 3240 3 32 324 3240 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 4 (.) 3 6 0 0 0 0 1
Body mass body B Bo Bod Body BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 4 (/) 3 10 0 0 0 0 1
<18.5 <18.5 <18.5 < <1 <18 <18. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 4 . 1 6 0 0 0 0 1
138 (1.5) 138 1 13 138 138 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 4 (.) 3 10 0 0 0 0 1
88 (1.7) 88 8 88 88 88 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 4 (.) 3 9 0 0 0 0 1
18.5-24.9 18.5-24.9 18.5-24.9 1 18 18. 18.5 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 4 .-. 3 8 0 0 0 0 1
2441 (27.3) 2441 2 24 244 2441 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 4 4 (.) 3 10 0 0 0 0 1
1428 (27.5) 1428 1 14 142 1428 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 4 4 (.) 3 10 0 0 0 0 1
25.0-29.9 25.0-29.9 25.0-29.9 2 25 25. 25.0 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 5 .-. 3 8 0 0 0 0 1
2840 (31.8) 2840 2 28 284 2840 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 4 5 (.) 3 10 0 0 0 0 1
1678 (32.3) 1678 1 16 167 1678 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 4 5 (.) 3 10 0 0 0 0 1
≥30 ≥30 ≥30 ≥ ≥3 ≥30 ≥30 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 5 no 0 3 0 0 0 0 1
2714 (30.4) 2714 2 27 271 2714 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 4 5 (.) 3 10 0 0 0 0 1
1626 (31.3) 1626 1 16 162 1626 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 4 5 (.) 3 10 0 0 0 0 1
Missing Missing missing M Mi Mis Miss BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 5 no 0 8 0 0 0 0 1
803 (9.0) 803 8 80 803 803 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 5 (.) 3 10 0 0 0 0 1
383 (7.4) 383 3 38 383 383 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 5 (.) 3 10 0 0 0 0 1
Alcohol use alcohol A Al Alc Alco BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 5 no 0 10 0 0 0 0 1
Non-user Non-user non-user N No Non Non- BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 5 - 1 7 0 0 0 0 1
1705 (19.1) 1705 1 17 170 1705 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 4 5 (.) 3 10 0 0 0 0 1
805 (15.5) 805 8 80 805 805 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 5 (.) 3 9 0 0 0 0 1
Low (1-14 low L Lo Low Low BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 4 6 (-/) 4 10 0 0 0 0 1
3854 (43.1) 3854 3 38 385 3854 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 6 (.) 3 5 0 0 0 0 1
2859 (55.0) 2859 2 28 285 2859 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 4 6 (.) 3 5 0 0 0 0 1
Moderate (15-21 moderate M Mo Mod Mode BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 6 (-/) 4 10 0 0 0 0 1
535 (6.0) 535 5 53 535 535 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 6 (.) 3 3 0 0 0 0 1
251 (4.8) 251 2 25 251 251 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 6 (.) 3 3 0 0 0 0 1
Hazardous (>21 hazardous H Ha Haz Haza BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 6 (/) 3 10 0 0 0 0 1
667 (7.5) 667 6 66 667 667 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 6 (.) 3 3 0 0 0 0 1
273 (5.3) 273 2 27 273 273 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 6 (.) 3 3 0 0 0 0 1
Ex-user Ex-user ex-user E Ex Ex- Ex-u BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 7 - 1 7 0 0 0 0 1
996 (11.2) 996 9 99 996 996 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 7 (.) 3 10 0 0 0 0 1
359 ((6.9) 359 3 35 359 359 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 7 ((.) 4 10 0 0 0 0 1
Missing Missing missing M Mi Mis Miss BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 7 no 0 6 0 0 0 0 1
1179 (13.2) 1179 1 11 117 1179 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 4 7 (.) 3 10 0 0 0 0 1
656 (12.6) 656 6 65 656 656 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 7 (.) 3 9 0 0 0 0 1
Inflammatory conditions inflammatory I In Inf Infl BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 7 no 0 10 0 0 0 0 1
Rheumatoid arthritis rheumatoid R Rh Rhe Rheu BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 7 no 0 10 0 0 0 0 1
6945 (77.7) 6945 6 69 694 6945 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 7 (.) 3 5 0 0 0 0 1
4067 (78.2) 4067 4 40 406 4067 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 7 (.) 3 5 0 0 0 0 1
Psoriatic arthritis psoriatic P Ps Pso Psor BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 7 no 0 10 0 0 0 0 1
1354 (15.2) 1354 1 13 135 1354 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 4 7 (.) 3 6 0 0 0 0 1
773 (14.9) 773 7 77 773 773 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 7 (.) 3 5 0 0 0 0 1
Inflammatory bowel inflammatory I In Inf Infl BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 7 no 0 10 0 0 0 0 1
319 (3.6) 319 3 31 319 319 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 7 (.) 3 3 0 0 0 0 1
173 (3.3) 173 1 17 173 173 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 7 (.) 3 3 0 0 0 0 1
Ankylosing spondylitis/reactive ankylosing A An Ank Anky BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 8 / 1 10 0 0 0 0 1
318 (3.6) 318 3 31 318 318 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 2 0 0 0 0 1
190 (3.7) 190 1 19 190 190 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 2 0 0 0 0 1
Comorbidities Comorbidities comorbidities C Co Com Como BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 8 no 0 10 0 0 0 0 1
Diabetes Diabetes diabetes D Di Dia Diab BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 no 0 8 0 0 0 0 1
982 (11.0) 982 9 98 982 982 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 10 0 0 0 0 1
519 (10.0) 519 5 51 519 519 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 10 0 0 0 0 1
Chronic kidney chronic C Ch Chr Chro BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 no 0 10 0 0 0 0 1
613 (6.9) 613 6 61 613 613 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 3 0 0 0 0 1
333 (6.4) 333 3 33 333 333 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 3 0 0 0 0 1
Immunosuppressive drugs immunosuppressive I Im Imm Immu BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 8 no 0 10 0 0 0 0 1
Methotrexate Methotrexate methotrexate M Me Met Meth BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 9 no 0 10 0 0 0 0 1
2999 (33.6) 2999 2 29 299 2999 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 4 9 (.) 3 9 0 0 0 0 1
1785 (34.3) 1785 1 17 178 1785 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 4 9 (.) 3 9 0 0 0 0 1
Leflunomide Leflunomide leflunomide L Le Lef Lefl BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 9 no 0 10 0 0 0 0 1
109 (1.2) 109 1 10 109 109 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 9 (.) 3 8 0 0 0 0 1
78 (1.5) 78 7 78 78 78 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 9 (.) 3 7 0 0 0 0 1
Azathioprine/Mercaptopurine Azathioprine/Mercaptopurine azathioprine/mercaptopurine A Az Aza Azat BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 9 / 1 10 0 0 0 0 1
73 (0.8) 73 7 73 73 73 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 9 (.) 3 3 0 0 0 0 1
41 (0.8) 41 4 41 41 41 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 9 (.) 3 3 0 0 0 0 1
Other drugs other O Ot Oth Othe BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 9 no 0 10 0 0 0 0 1
Statins Statins statins S St Sta Stat BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 9 no 0 6 0 0 0 0 1
2088 (23.4) 2088 2 20 208 2088 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 4 9 (.) 3 10 0 0 0 0 1
1130 (21.7) 1130 1 11 113 1130 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 4 9 (.) 3 10 0 0 0 0 1
Carbamazepine/Valproate Carbamazepine/Valproate carbamazepine/valproate C Ca Car Carb BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 9 / 1 10 0 1 0 0 1
103 (1.2) 103 1 10 103 103 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 9 (.) 3 4 0 1 0 0 1
37 (0.7) 37 3 37 37 37 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 9 (.) 3 3 0 1 0 0 1
Paracetamol Paracetamol paracetamol P Pa Par Para BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 no 0 2 0 1 0 0 1
1445 (16.2) 1445 1 14 144 1445 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 4 10 (.) 3 2 0 1 0 0 1
884 (17.0) 884 8 88 884 884 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 10 (.) 3 2 0 1 0 0 1
At least at A At At At BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 10 no 0 10 0 1 0 0 1
6 months 6 6 6 6 6 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 10 - 1 7 0 1 0 0 1
1264 (14.2) 1264 1 12 126 1264 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 4 10 (.) 3 10 0 1 0 0 1
753 (14.5) 753 7 75 753 753 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 10 (.) 3 9 0 1 0 0 1
*Values are *values * *V *Va *Val BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 10 *(). 4 10 0 1 0 0 1
CPRD, Clinical cprd, C CP CPR CPRD BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 ,. 2 7 0 1 0 0 1
RMD Open: rmd R RM RMD RMD BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 11 :./--.://... 12 10 0 0 0 0 1
Protected by protected P Pr Pro Prot BLOCKSTART PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 11 ,,,. 4 10 0 0 1 0 1
5 5 5 5 5 5 5 BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 0 no 0 10 0 1 0 0 0
Abhishek A, abhishek A Ab Abh Abhi BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 0 ,.;:.:./-- 10 10 0 1 1 0 0
Epidemiology Epidemiology epidemiology E Ep Epi Epid BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 10 0 1 0 0 0
comparing two comparing c co com comp BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 / 1 8 0 1 0 0 1
median of median m me med medi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ., 2 10 0 1 0 0 1
a measure a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 4 0 no 0 8 0 1 0 0 1
calculated. calculated. calculated. c ca cal calc BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 . 1 2 0 1 0 0 1
Model external model M Mo Mod Mode BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 4 0 0 0 0 1
External validation external E Ex Ext Exte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 8 0 0 0 0 1
using data using u us usi usin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 . 1 8 0 0 0 0 1
equation was equation e eq equ equa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 ,- 2 9 0 0 0 0 1
bration and bration b br bra brat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 no 0 8 0 0 0 0 1
same measures same s sa sam same BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 .- 2 10 0 0 0 0 1
examined by examined e ex exa exam BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 8 0 0 0 0 1
from the from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 .- 2 9 0 0 0 0 1
bration plot, bration b br bra brat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 , 1 9 0 0 0 0 1
into 10 into i in int into BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 .,- 3 8 0 0 0 0 1
observations were observations o ob obs obse BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 9 0 0 0 0 1
curves across curves c cu cur curv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 - 1 9 0 0 0 0 1
smoother. Separate smoother. s sm smo smoo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 .- 2 9 0 0 0 0 1
tion of tion t ti tio tion BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 no 0 9 0 0 0 0 1
is shown is i is is is BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 . 1 9 0 1 0 0 1
age group age a ag age age BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 (). 3 9 0 1 0 0 1
Stata-MP V.16 stata-mp S St Sta Stat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 3 -.. 3 10 0 1 0 0 1
study was study s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 no 0 10 0 1 0 0 1
of a of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 - 1 9 0 1 0 0 1
tion or tion t ti tio tion BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 3 . 1 5 0 1 0 0 1
RESULTS RESULTS results R RE RES RESU BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 1 1 0 0 0 0 0 4 3 no 0 1 0 0 0 0 1
Study participants study S St Stu Stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 3 no 0 3 0 0 0 0 1
Data for data D Da Dat Data BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 3 no 0 9 0 0 0 0 1
and 12 and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 -- 2 9 0 0 0 0 1
derivation and derivation d de der deri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 ,( 2 9 0 0 0 0 1
supplemental figures supplemental s su sup supp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 ). 2 9 0 0 0 0 1
both cohorts both b bo bot both BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 , 1 8 0 0 0 0 1
had similar had h ha had had BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 , 1 10 0 0 0 0 1
and drug and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 (). 3 9 0 0 0 0 1
(21 parameters) (21 ( (2 (21 (21 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 3 ()(). 5 9 0 0 0 0 1
Table 2 table T Ta Tab Tabl BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 5 - 1 10 0 0 0 0 1
Adjusted HR adjusted A Ad Adj Adju BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 5 () 2 10 0 0 0 0 1
β-Coefficients β-Coefficients β-coefficients β β- β-C β-Co BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 5 - 1 7 0 0 0 0 1
Age, mean age, A Ag Age Age, BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 5 ,() 3 10 0 0 0 0 1
1.01 (1.00 1.01 1 1. 1.0 1.01 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 5 .(..) 5 10 0 0 0 0 1
0.0076439 0.0076439 0.0076439 0 0. 0.0 0.00 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 5 . 1 5 0 0 0 0 1
Female sex female F Fe Fem Fema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 5 no 0 5 0 0 0 0 1
1.08 (0.88 1.08 1 1. 1.0 1.08 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 5 .(..) 5 10 0 0 0 0 1
0.0741336 0.0741336 0.0741336 0 0. 0.0 0.07 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 5 5 . 1 5 0 0 0 0 1
Body mass body B Bo Bod Body BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 6 no 0 8 0 0 0 0 1
0.98 (0.97 0.98 0 0. 0.9 0.98 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 6 .(..) 5 10 0 0 0 0 1
-0.0168035 -0.0168035 -0.0168035 - -0 -0. -0.0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 5 6 -. 2 5 0 0 0 0 1
Alcohol use alcohol A Al Alc Alco BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 6 no 0 10 0 0 0 0 1
Non-user Non-user non-user N No Non Non- BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 6 - 1 9 0 0 0 0 1
Reference Reference reference R Re Ref Refe BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 6 no 0 10 0 0 0 0 1
Low (1-14 low L Lo Low Low BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 5 6 (-/) 4 10 0 0 0 0 1
1.02 (0.80 1.02 1 1. 1.0 1.02 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 6 .(..) 5 9 0 0 0 0 1
0.0182851 0.0182851 0.0182851 0 0. 0.0 0.01 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 5 6 . 1 4 0 0 0 0 1
Moderate (15-21 moderate M Mo Mod Mode BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 6 (-/) 4 10 0 0 0 0 1
0.64 (0.38 0.64 0 0. 0.6 0.64 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 6 .(..) 5 7 0 0 0 0 1
-0.4507257 -0.4507257 -0.4507257 - -0 -0. -0.4 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 6 -. 2 3 0 0 0 0 1
Hazardous (>21 hazardous H Ha Haz Haza BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 7 (/) 3 10 0 0 0 0 1
0.87 (0.58 0.87 0 0. 0.8 0.87 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 7 .(..) 5 7 0 0 0 0 1
-0.133557 -0.133557 -0.133557 - -0 -0. -0.1 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 5 7 -. 2 3 0 0 0 0 1
Ex-user Ex-user ex-user E Ex Ex- Ex-u BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 7 - 1 4 0 0 0 0 1
0.94 (0.67 0.94 0 0. 0.9 0.94 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 7 .(..) 5 10 0 0 0 0 1
-0.0651469 -0.0651469 -0.0651469 - -0 -0. -0.0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 5 7 -. 2 5 0 0 0 0 1
Inflammatory conditions inflammatory I In Inf Infl BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 7 no 0 10 0 0 0 0 1
Rheumatoid arthritis rheumatoid R Rh Rhe Rheu BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 7 no 0 10 0 0 0 0 1
Reference Reference reference R Re Ref Refe BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 7 no 0 4 0 0 0 0 1
Psoriatic arthritis psoriatic P Ps Pso Psor BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 7 no 0 10 0 0 0 0 1
1.03 (0.78 1.03 1 1. 1.0 1.03 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 7 .(..) 5 10 0 0 0 0 1
0.0316689 0.0316689 0.0316689 0 0. 0.0 0.03 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 5 7 . 1 5 0 0 0 0 1
Inflammatory bowel inflammatory I In Inf Infl BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 8 no 0 10 0 0 0 0 1
0.74 (0.38 0.74 0 0. 0.7 0.74 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 8 .(..) 5 7 0 0 0 0 1
-0.305206 -0.305206 -0.305206 - -0 -0. -0.3 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 8 -. 2 3 0 0 0 0 1
Ankylosing spondylitis/reactive ankylosing A An Ank Anky BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 8 / 1 10 0 0 0 0 1
1.25 (0.74 1.25 1 1. 1.2 1.25 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 8 .(..) 5 4 0 0 0 0 1
0.2214547 0.2214547 0.2214547 0 0. 0.2 0.22 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 5 8 . 1 2 0 0 0 0 1
Comorbidities Comorbidities comorbidities C Co Com Como BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 8 no 0 10 0 0 0 0 1
Diabetes Diabetes diabetes D Di Dia Diab BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 8 no 0 4 0 0 0 0 1
1.34 (1.01 1.34 1 1. 1.3 1.34 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 8 .(..) 5 10 0 0 0 0 1
0.2909969 0.2909969 0.2909969 0 0. 0.2 0.29 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 5 8 . 1 5 0 0 0 0 1
Chronic kidney chronic C Ch Chr Chro BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 8 no 0 10 0 0 0 0 1
1.96 (1.47 1.96 1 1. 1.9 1.96 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 8 .(..) 5 6 0 0 0 0 1
0.671859 0.671859 0.671859 0 0. 0.6 0.67 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 5 8 . 1 2 0 0 0 0 1
Immunosuppressive drugs immunosuppressive I Im Imm Immu BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 9 no 0 10 0 0 0 0 1
Methotrexate Methotrexate methotrexate M Me Met Meth BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 9 no 0 6 0 0 0 0 1
1.39 (1.15 1.39 1 1. 1.3 1.39 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 .(..) 5 10 0 0 0 0 1
0.3315573 0.3315573 0.3315573 0 0. 0.3 0.33 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 5 9 . 1 5 0 0 0 0 1
Leflunomide Leflunomide leflunomide L Le Lef Lefl BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 9 no 0 6 0 0 0 0 1
2.05 (1.09 2.05 2 2. 2.0 2.05 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 .(..) 5 10 0 0 0 0 1
0.7164324 0.7164324 0.7164324 0 0. 0.7 0.71 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 5 9 . 1 5 0 0 0 0 1
Azathioprine/Mercaptopurine Azathioprine/Mercaptopurine azathioprine/mercaptopurine A Az Aza Azat BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 9 / 1 10 0 0 0 0 1
1.24 (0.37 1.24 1 1. 1.2 1.24 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 .(..) 5 7 0 0 0 0 1
0.2189764 0.2189764 0.2189764 0 0. 0.2 0.21 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 5 9 . 1 3 0 0 0 0 1
Other drugs other O Ot Oth Othe BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 9 no 0 10 0 0 0 0 1
Statins Statins statins S St Sta Stat BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 9 no 0 4 0 0 0 0 1
0.98 (0.78 0.98 0 0. 0.9 0.98 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 .(..) 5 10 0 0 0 0 1
-0.0181917 -0.0181917 -0.0181917 - -0 -0. -0.0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 5 9 -. 2 5 0 0 0 0 1
Carbamazepine/Valproate Carbamazepine/Valproate carbamazepine/valproate C Ca Car Carb BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 10 / 1 10 0 0 0 0 1
0.74 (0.28 0.74 0 0. 0.7 0.74 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 .(..) 5 8 0 0 0 0 1
-0.2949835 -0.2949835 -0.2949835 - -0 -0. -0.2 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 5 10 -. 2 4 0 0 0 0 1
Paracetamol Paracetamol paracetamol P Pa Par Para BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 10 no 0 6 0 1 0 0 1
1.14 (0.90 1.14 1 1. 1.1 1.14 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 .(..) 5 10 0 1 0 0 1
0.1272515 0.1272515 0.1272515 0 0. 0.1 0.12 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 5 10 . 1 5 0 1 0 0 1
Blood-test abnormalities blood-test B Bl Blo Bloo BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 10 - 1 4 0 1 0 0 1
At least at A At At At BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 10 no 0 10 0 1 0 0 1
6 months 6 6 6 6 6 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 10 - 1 7 0 1 0 0 1
2.80 (2.29 2.80 2 2. 2.8 2.80 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 .(..) 5 10 0 1 0 0 1
1.029245 1.029245 1.029245 1 1. 1.0 1.02 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 5 10 . 1 4 0 1 0 0 1
*The reported *the * *T *Th *The BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 11 *. 2 10 0 1 0 0 1
RMD Open: rmd R RM RMD RMD BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 11 :./--.://... 12 10 0 0 0 0 0
Protected by protected P Pr Pro Prot BLOCKSTART PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 11 ,,,. 4 10 0 0 1 0 0
6 6 6 6 6 6 6 BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 0 no 0 10 0 1 0 0 0
Abhishek A, abhishek A Ab Abh Abhi BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 ,.;:.:./-- 10 10 0 1 1 0 0
RMD Open rmd R RM RMD RMD BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 no 0 10 0 1 0 0 0
RMD Open rmd R RM RMD RMD BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 no 0 10 0 1 0 0 0
RMD Open rmd R RM RMD RMD BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 no 0 10 0 1 0 0 0
Model development model M Mo Mod Mode BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 2 0 0 0 0 1
In the in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 5 0 , 1 9 0 0 0 0 1
during the during d du dur duri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 -(). 4 9 0 0 0 0 1
(18.55 to (18.55 ( (1 (18 (18. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 0 (..)-.,, 8 9 0 0 0 0 1
131 and 131 1 13 131 131 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 0 , 1 9 0 0 0 0 1
to cytopenia, to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 , 1 9 0 0 0 0 1
enzymes. Outcome enzymes. e en enz enzy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 . 1 8 0 0 0 0 1
revealed that revealed r re rev reve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 .()- 4 8 0 0 0 0 1
tially be tially t ti tia tial BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 no 0 9 0 0 0 0 1
or its or o or or or BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ,. 2 10 0 0 0 0 1
(online supplemental (online ( (o (on (onl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 (). 3 5 0 0 0 0 1
Outcome events outcome O Ou Out Outc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 -- 2 8 0 0 0 0 1
period when period p pe per peri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ( 1 8 0 0 0 0 1
supplemental figure supplemental s su sup supp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 )- 2 9 0 0 0 0 1
either methotrexate either e ei eit eith BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 8 0 0 0 0 1
sulfasalazine were sulfasalazine s su sul sulf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 ( 1 9 0 0 0 0 1
S4). CKD s4). S S4 S4) S4). BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 0 ).,(),-- 8 9 0 0 0 0 1
scription of scription s sc scr scri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 ,-- 3 8 0 0 0 0 1
mide and mide m mi mid mide BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 no 0 8 0 0 0 0 1
during first during d du dur duri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 9 0 0 0 0 1
strong predictors strong s st str stro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 5 0 no 0 9 0 0 0 0 1
HR (95% hr H HR HR HR BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 5 0 ().(..),.(..),. 15 9 0 0 0 0 1
(1.15 to (1.15 ( (1 (1. (1.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 0 (..),.(..).(..), 16 10 0 0 0 0 1
respectively (table respectively r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ()., 4 8 0 0 0 0 1
shrinkage factor shrinkage s sh shr shri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 . 1 9 0 0 0 0 1
predictor coefficients predictor p pr pre pred BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 no 0 9 0 0 0 0 1
and after and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 -,' 3 8 0 0 0 0 1
baseline survival baseline b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 (). 3 9 0 0 0 0 1
follow-up (Box follow-up f fo fol foll BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 -(). 4 3 0 0 0 0 1
Model performance model M Mo Mod Mode BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 3 no 0 7 0 1 0 0 1
As expected, as A As As As BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 3 ,()- 4 10 0 1 0 0 1
opment data opment o op opm opme BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 3 .(..). 6 10 0 1 0 0 1
the final the t th the the BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 (,) 3 9 0 0 0 0 1
that the that t th tha that BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 no 0 9 0 0 0 0 1
observed outcome observed o ob obs obse BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 no 0 8 0 0 0 0 1
patients, with patients, p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 ,-( 3 9 0 0 0 0 1
prediction line) prediction p pr pre pred BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 )(). 4 9 0 0 0 0 1
risk of risk r ri ris risk BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 (), 3 9 0 0 0 0 1
of the of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 - 1 9 0 0 0 0 1
tion plot tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 3 (). 3 9 0 0 0 0 1
calibration curve calibration c ca cal cali BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 no 0 9 0 0 0 0 1
risk to risk r ri ris risk BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 -- 2 9 0 0 0 0 1
abilities (figure abilities a ab abi abil BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 ()..( 5 10 0 0 0 0 1
CI 0.77 ci C CI CI CI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 3 ..),() 6 8 0 0 0 0 1
2.48 (2.16 2.48 2 2. 2.4 2.48 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 3 .(..) 5 9 0 0 0 0 1
were above were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 no 0 9 0 0 0 0 1
the median. the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 . 1 9 0 0 0 0 1
was 0.79, was w wa was was BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 3 .,.(). 6 8 0 0 0 0 1
Model performance model M Mo Mod Mode BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 5 no 0 7 0 0 0 0 1
There were there T Th The Ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 5 (). 3 8 0 0 0 0 1
(19.36 to (19.36 ( (1 (19 (19. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 (..)/- 6 8 0 0 0 0 1
cohort. The cohort. c co coh coho BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 .()- 4 9 0 0 0 0 1
follow-up period follow-up f fo fol foll BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 -.(..)(). 9 9 0 0 0 0 1
calibration plot calibration c ca cal cali BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 no 0 8 0 0 0 0 1
between observed between b be bet betw BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 no 0 9 0 0 0 0 1
tenths of tenths t te ten tent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 (). 3 9 0 0 0 0 1
the deciles the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 no 0 9 0 0 0 0 1
plot due plot p pl plo plot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 ( 1 9 0 0 0 0 1
supplemental figures supplemental s su sup supp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 ). 2 9 0 0 0 0 1
were plotted, were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 , 1 8 0 0 0 0 1
alignment of alignment a al ali alig BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 no 0 9 0 0 0 0 1
risk and risk r ri ris risk BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 no 0 9 0 0 0 0 1
at high-risk at a at at at BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 -(). 4 9 0 0 0 0 1
was also was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 ,,( 3 9 0 0 0 0 1
figures S9-S12) figures f fi fig figu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 -) 2 9 0 0 0 0 1
overprediction of overprediction o ov ove over BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 . 1 10 0 0 0 0 1
the validation the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 .(..), 6 9 0 0 0 0 1
to an to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 ().(..).- 9 9 0 0 0 0 1
ination in ination i in ina inat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 no 0 9 0 0 0 0 1
similar (table similar s si sim simi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 (). 3 8 0 0 0 0 1
younger or younger y yo you youn BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 6 5 , 1 9 0 0 0 0 1
conditions (online conditions c co con cond BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 (). 3 8 0 0 0 0 1
Worked examples: worked W Wo Wor Work BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 5 :, 2 8 0 0 0 0 1
one from one o on one one BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 no 0 8 0 0 0 0 1
by deciles by b by by by BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 - 1 9 0 0 0 0 1
opment cohort, opment o op opm opme BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 , 1 8 0 0 0 0 1
the risk, the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 ,. 2 9 0 0 0 0 1
cumulative probability cumulative c cu cum cumu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 no 0 8 0 0 0 0 1
from 5.3% from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 .. 2 9 0 0 0 0 1
middle of middle m mi mid midd BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 ,. 2 9 0 0 0 0 1
the 10th the t th the the BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 (). 3 7 0 0 0 0 1
DISCUSSION DISCUSSION discussion D DI DIS DISC BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 6 8 no 0 1 0 1 0 0 1
We have we W We We We BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 8 no 0 9 0 1 0 0 1
model for model m mo mod mode BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 8 no 0 9 0 1 0 0 1
blood-test results. blood-test b bl blo bloo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 8 -., 3 9 0 1 0 0 1
the first the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 8 -. 2 10 0 1 0 0 1
predicting outcomes predicting p pr pre pred BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 8 no 0 9 0 1 0 0 1
Box 1 box B Bo Box Box BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 6 9 no 0 8 0 1 0 0 1
discontinuation after discontinuation d di dis disc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 9 no 0 10 0 1 0 0 1
within the within w wi wit with BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 9 no 0 3 0 1 0 0 1
Risk score=1-0.940 risk R Ri Ris Risk BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 9 -.(.),. 7 8 0 0 0 0 1
years at years y ye yea year BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 9 . 1 8 0 0 0 0 1
sex-0.0168035×BMI+0.0182851×low alcohol sex-0.0168035×bmi+0.0182851×low s se sex sex- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 9 -.. 3 5 0 0 0 0 1
intake-0.4507257×moderate alcohol intake-0.4507257×moderate i in int inta BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 -.-. 4 8 0 0 0 0 1
alcohol intake-0.0651469×e alcohol a al alc alco BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 9 -.-. 4 8 0 0 0 0 1
soriasis-0.305206×IBD+0.2214547× ankylosing soriasis-0.305206×ibd+0.2214547× s so sor sori BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 9 -../ 4 8 0 0 0 0 1
reactive arthritis+0.2909969×diabetes+ reactive r re rea reac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 9 .. 2 7 0 0 0 0 1
+0.3315573×MTX+0.7164324×LEF+0.2189764× AZA +0.3315573×mtx+0.7164324×lef+0.2189764× + +0 +0. +0.3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 9 ... 3 6 0 0 0 0 1
6-MP-0.0181917×statins-0.2949835×carbamazepine/ valproate 6-mp-0.0181917×statins-0.2949835×carbamazepine/ 6 6- 6-M 6-MP BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 9 --.-./ 6 8 0 0 0 0 1
+0.1272515×paracetamol+1.029245×at least +0.1272515×paracetamol+1.029245×at + +0 +0. +0.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 6 9 .. 2 8 0 0 0 0 1
liver enzyme liver l li liv live BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 9 no 0 10 0 0 0 0 1
prescription. prescription. prescription. p pr pre pres BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 9 . 1 2 0 0 0 0 1
All variables all A Al All All BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 10 ,,, 3 5 0 0 0 0 1
BMI and bmi B BM BMI BMI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 10 .,. 3 5 0 0 0 0 1
survival function, survival s su sur surv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 10 ,. 2 5 0 0 0 0 1
the estimated the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 10 , 1 5 0 0 0 0 1
mutually adjusted mutually m mu mut mutu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 10 . 1 4 0 0 0 0 1
AZA, azathioprine; aza, A AZ AZA AZA, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 10 ,;,;,; 6 4 0 0 0 0 1
IBD, inflammatory ibd, I IB IBD IBD, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 10 ,;,;,; 6 4 0 0 0 0 1
MTX, methotrexate. mtx, M MT MTX MTX, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 10 ,. 2 1 0 0 0 0 1
RMD Open: rmd R RM RMD RMD BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 10 :./--.://... 12 10 0 0 0 0 1
Protected by protected P Pr Pro Prot BLOCKSTART PAGEEND NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 11 ,,,. 4 10 0 0 1 0 1
7 7 7 7 7 7 7 BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 0 no 0 10 0 1 0 0 0
Abhishek A, abhishek A Ab Abh Abhi BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 ,.;:.:./-- 10 10 0 1 1 0 0
Epidemiology Epidemiology epidemiology E Ep Epi Epid BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 10 1 1 0 0 0
Figure 1 figure F Fi Fig Figu BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 - 1 10 1 0 0 0 1
years in years y ye yea year BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 .;().. 6 7 1 0 0 0 1
Table 3 table T Ta Tab Tabl BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 2 no 0 10 1 0 0 0 1
Measure Measure measure M Me Mea Meas BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 2 no 0 10 0 0 0 0 1
Apparent Apparent apparent A Ap App Appa BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 2 no 0 2 1 0 0 0 1
performance* Test performance* p pe per perf BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 2 * 1 10 1 0 0 0 1
Average Average average A Av Ave Aver BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 2 no 0 7 1 0 0 0 1
optimism ‡ optimism o op opt opti BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 no 0 10 1 0 0 0 1
Optimism corrected optimism O Op Opt Opti BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 2 no 0 10 1 0 0 0 1
performance § performance p pe per perf BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 2 no 0 7 1 0 0 0 1
External validation external E Ex Ext Exte BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 2 no 0 10 1 0 0 0 1
(CPRD Aurum) (cprd ( (C (CP (CPR BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 7 2 () 2 7 1 0 0 0 1
Overall calibration overall O Ov Ove Over BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 3 no 0 10 0 0 0 0 1
1.00 (0.85 1.00 1 1. 1.0 1.00 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 3 .(. 3 5 0 0 0 0 1
1.15) 1.15) 1.15) 1 1. 1.1 1.15 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 3 .) 2 2 0 0 0 0 1
0.84 (0.70 0.84 0 0. 0.8 0.84 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 3 .(..) 5 10 0 0 0 0 1
0.16 0.16 0.16 0 0. 0.1 0.16 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 3 . 1 2 0 0 0 0 1
0.84 (0.69 0.84 0 0. 0.8 0.84 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 3 .(..) 5 10 0 0 0 0 1
1.19 (0.96 1.19 1 1. 1.1 1.19 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 3 .(..) 5 10 0 0 0 0 1
R 2 r R R R R BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 7 4 no 0 10 0 0 0 0 1
D D d D D D D BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 7 4 no 0 10 0 0 0 0 1
0.17 (0.12 0.17 0 0. 0.1 0.17 BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 4 .(. 3 10 0 0 0 0 1
0.21) 0.21) 0.21) 0 0. 0.2 0.21 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 4 .) 2 4 0 0 0 0 1
0.15 (0.11 0.15 0 0. 0.1 0.15 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 4 .(..) 5 10 0 0 0 0 1
0.04 0.04 0.04 0 0. 0.0 0.04 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 4 . 1 2 0 0 0 0 1
0.13 (0.08 0.13 0 0. 0.1 0.13 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 4 .(..) 5 10 0 0 0 0 1
0.15 (0.10 0.15 0 0. 0.1 0.15 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 4 .(..) 5 10 0 0 0 0 1
Royston D royston R Ro Roy Roys BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 5 no 0 10 0 0 0 0 1
0.91 (0.77 0.91 0 0. 0.9 0.91 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .(. 3 7 0 0 0 0 1
1.05) 1.05) 1.05) 1 1. 1.0 1.05 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 5 .) 2 3 0 0 0 0 1
0.85 (0.72 0.85 0 0. 0.8 0.85 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 6 .(..) 5 10 0 0 0 0 1
0.12 0.12 0.12 0 0. 0.1 0.12 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 6 . 1 2 0 0 0 0 1
0.79 (0.65 0.79 0 0. 0.7 0.79 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 6 .(..) 5 10 0 0 0 0 1
0.87 (0.67 0.87 0 0. 0.8 0.87 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 6 .(..) 5 10 0 0 0 0 1
*Refers to *refers * *R *Re *Ref BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 7 *(). 4 7 0 1 0 0 1
†Determined by †determined † †D †De †Det BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 7 (), 3 10 0 1 0 0 1
applying same applying a ap app appl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 7 . 1 3 0 1 0 0 1
‡Average difference ‡average ‡ ‡A ‡Av ‡Ave BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 7 . 1 8 0 1 0 0 1
§Subtracting average §subtracting § §S §Su §Sub BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 7 . 1 4 0 1 0 0 1
¶Penalised model ¶penalised ¶ ¶P ¶Pe ¶Pen BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 7 (:.;..). 8 7 0 1 0 0 1
CPRD, Clinical cprd, C CP CPR CPRD BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 7 7 ,. 2 3 0 1 0 0 1
RMD Open: rmd R RM RMD RMD BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 7 10 :./--.://... 12 10 0 0 0 0 0
Protected by protected P Pr Pro Prot BLOCKSTART PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 11 ,,,. 4 10 0 0 1 0 0
8 8 8 8 8 8 8 BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 0 no 0 10 0 1 0 0 0
Abhishek A, abhishek A Ab Abh Abhi BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 ,.;:.:./-- 10 10 0 1 1 0 0
RMD Open rmd R RM RMD RMD BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 10 1 1 0 0 0
RMD Open rmd R RM RMD RMD BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 10 1 1 0 0 0
RMD Open rmd R RM RMD RMD BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 10 1 1 0 0 0
subgroups defined subgroups s su sub subg BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 . 1 8 1 0 0 0 1
Previous studies previous P Pr Pre Prev BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 -- 2 9 1 0 0 0 1
ferase 2 ferase f fe fer fera BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 (-) 3 9 1 0 0 0 1
sulfasalazine toxicity. sulfasalazine s su sul sulf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 .,- 3 9 1 0 0 0 1
ated all ated a at ate ated BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 9 1 0 0 0 1
myelotoxicity, hepatotoxicity myelotoxicity, m my mye myel BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 ,- 2 9 1 0 0 0 1
ated in ated a at ate ated BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 . 1 4 1 0 0 0 1
Our findings our O Ou Our Our BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 --- 3 9 1 0 0 0 1
to monitoring to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 , 1 9 1 0 0 0 1
3 monthly 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 0 - 1 8 1 0 0 0 1
treatment as treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 1 0 0 0 1
characteristics and characteristics c ch cha char BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ,- 2 8 1 0 0 0 1
toring for toring t to tor tori BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 9 1 0 0 0 1
recommended in recommended r re rec reco BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 - 1 8 1 0 0 0 1
priate because priate p pr pri pria BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 9 1 0 0 0 1
in the in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 0 . 1 9 1 0 0 0 1
variation in variation v va var vari BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 1 0 0 0 1
monitor some monitor m mo mon moni BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 10 1 0 0 0 1
treatment, while treatment, t tr tre trea BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 , 1 9 1 0 0 0 1
monitored frequently, monitored m mo mon moni BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 ,,. 3 7 1 0 0 0 1
It is it I It It It BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 5 no 0 9 1 0 0 0 1
and annual and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 no 0 9 1 0 0 0 1
to improve to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 . 1 8 1 0 0 0 1
propose threshold propose p pr pro prop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 no 0 9 1 0 0 0 1
blood tests blood b bl blo bloo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 . 1 9 1 0 0 0 1
taken by taken t ta tak take BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 5 ., 2 8 1 0 0 0 1
ought to ought o ou oug ough BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 . 1 8 1 0 0 0 1
It is it I It It It BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 5 no 0 9 1 0 0 0 1
used to used u us use used BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 - 1 9 1 0 0 0 1
on sulfasalazine on o on on on BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 no 0 9 1 0 0 0 1
from patients from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 no 0 9 1 0 0 0 1
6 months 6 6 6 6 6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 7 5 - 1 9 1 0 0 0 1
in a in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 5 .- 2 9 1 0 0 0 1
stabilise a stabilise s st sta stab BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 5 ' 1 10 1 0 0 0 1
and monitoring and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 . 1 9 1 0 0 0 1
systems where systems s sy sys syst BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 5 no 0 8 1 0 0 0 1
Figure 2 figure F Fi Fig Figu BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 9 - 1 10 1 0 0 0 1
years in years y ye yea year BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 9 .;().. 6 7 1 0 0 0 1
RMD Open: rmd R RM RMD RMD BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 10 :./--.://... 12 10 0 0 0 0 1
Protected by protected P Pr Pro Prot BLOCKSTART PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 11 ,,,. 4 10 0 0 1 0 1
9 9 9 9 9 9 9 BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 0 no 0 10 0 1 0 0 0
Abhishek A, abhishek A Ab Abh Abhi BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ,.;:.:./-- 10 10 0 1 1 0 0
Epidemiology Epidemiology epidemiology E Ep Epi Epid BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 10 0 1 0 0 0
exist, this exist, e ex exi exis BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ,- 2 9 0 0 0 0 1
alazine treatment. alazine a al ala alaz BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 . 1 9 0 0 0 0 1
safe, sulfasalazine safe, s sa saf safe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 , 1 10 0 0 0 0 1
nephrotoxicity comparable nephrotoxicity n ne nep neph BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 - 1 9 0 0 0 0 1
trexate in trexate t tr tre trex BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 . 1 5 0 0 0 0 1
CKD stage ckd C CK CKD CKD BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 , 1 8 0 0 0 0 1
or leflunomide or o or or or BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 9 0 0 0 0 1
discontinuation with discontinuation d di dis disc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 - 1 8 0 0 0 0 1
results in results r re res resu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 0 . 1 9 0 0 0 0 1
reduced sulfasalazine reduced r re red redu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 9 0 0 0 0 1
associated with associated a as ass asso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 .- 2 9 0 0 0 0 1
during the during d du dur duri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 9 0 0 0 0 1
discontinuing sulfasalazine discontinuing d di dis disc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 8 0 0 0 0 1
blood-test results, blood-test b bl blo bloo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 -, 2 9 0 0 0 0 1
leflunomide. 24 leflunomide. l le lef lefl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 . 1 9 0 0 0 0 1
before starting before b be bef befo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 9 0 0 0 0 1
with abnormal with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 - 1 9 0 0 0 0 1
methotrexate and methotrexate m me met meth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ,.- 3 8 0 0 0 0 1
There are there T Th The Ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 0 ., 2 10 0 0 0 0 1
large real-world large l la lar larg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 0 - 1 9 0 0 0 0 1
model development model m mo mod mode BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 8 0 0 0 0 1
for external for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ., 2 9 0 0 0 0 1
included patients included i in inc incl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 9 0 0 0 0 1
have broad have h ha hav have BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ., 2 9 0 0 0 0 1
were selected were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 9 0 0 0 0 1
on clinical on o on on on BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ., 2 9 0 0 0 0 1
abnormal blood-test abnormal a ab abn abno BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 -- 2 9 0 0 0 0 1
zine discontinuation, zine z zi zin zine BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ,, 2 9 0 0 0 0 1
clinically relevant clinically c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ., 2 9 0 0 0 0 1
is easy is i is is is BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 , 1 10 0 0 0 0 1
electronic health electronic e el ele elec BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 . 1 4 0 0 0 0 1
However, several however, H Ho How Howe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 0 , 1 8 0 0 0 0 1
be considered. be b be be be BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ., 2 9 0 0 0 0 1
when the when w wh whe when BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 9 0 0 0 0 1
hospital clinic. hospital h ho hos hosp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 .,- 3 9 0 0 0 0 1
rent use rent r re ren rent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 . 1 9 0 0 0 0 1
However, there however, H Ho How Howe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 0 , 1 9 0 0 0 0 1
increase sulfasalazine increase i in inc incr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ., 2 9 0 0 0 0 1
data on data d da dat data BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 9 0 0 0 0 1
CPRD. Fourth, cprd. C CP CPR CPRD BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ., 2 9 0 0 0 0 1
a different a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 8 0 ., 2 9 0 0 0 0 1
only 4.5% only o on onl only BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 . 1 8 0 0 0 0 1
in this in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 0 - 1 9 0 0 0 0 1
nate illness nate n na nat nate BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 8 0 .,- 3 10 0 0 0 0 1
dation studies dation d da dat dati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ,. 2 9 0 0 0 0 1
blood-test results blood-test b bl blo bloo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 - 1 9 0 0 0 0 1
illness. 25 illness. i il ill illn BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ., 2 10 0 0 0 0 1
was distinct was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 , 1 9 0 0 0 0 1
originated from originated o or ori orig BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 . 1 8 0 0 0 0 1
therefore that therefore t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 9 0 0 0 0 1
another country. another a an ano anot BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 .,(.) 5 9 0 0 0 0 1
the highest the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 9 0 0 0 0 1
of risk, of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 , 1 9 0 0 0 0 1
these groups. these t th the thes BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ., 2 8 0 0 0 0 1
risk regression. risk r ri ris risk BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ., 2 9 0 0 0 0 1
of our of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 ((.)) 5 9 0 0 0 0 1
the derivation the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 (.) 3 9 0 0 0 0 1
cohort up cohort c co coh coho BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 --., 4 9 0 0 0 0 1
retrospective analysis retrospective r re ret retr BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 no 0 9 0 0 0 0 1
during routine during d du dur duri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 no 0 8 0 0 0 0 1
were not were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ., 2 9 0 0 0 0 1
any bias any a an any any BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 no 0 9 0 0 0 0 1
of all of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 - 1 9 0 0 0 0 1
alazine within alazine a al ala alaz BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 no 0 9 0 0 0 0 1
criteria. criteria. criteria. c cr cri crit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 . 1 1 0 0 0 0 1
In conclusion, in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 8 5 ,- 2 8 0 0 0 0 1
dated a dated d da dat date BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 - 1 9 0 0 0 0 1
tion with tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 5 -. 2 9 0 0 0 0 1
findings need findings f fi fin find BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 - 1 8 0 0 0 0 1
national specialist national n na nat nati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 ' 1 10 0 0 0 0 1
decide on decide d de dec deci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 - 1 9 0 0 0 0 1
tests during tests t te tes test BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 -. 2 8 0 0 0 0 1
Author affiliations author A Au Aut Auth BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 5 no 0 10 0 0 0 0 1
1 1 1 1 1 1 1 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 9 6 no 0 10 0 0 0 0 1
Academic Rheumatology, academic A Ac Aca Acad BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 6 ,,, 3 10 0 0 0 0 1
2 2 2 2 2 2 2 BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 9 6 no 0 10 0 0 0 0 1
Lifespan and lifespan L Li Lif Life BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 6 ,,, 3 10 0 0 0 0 1
3 3 3 3 3 3 3 BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 9 6 no 0 10 0 0 0 0 1
Centre for centre C Ce Cen Cent BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 9 6 ,,, 3 10 0 0 0 0 1
4 4 4 4 4 4 4 BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 9 6 no 0 10 0 0 0 0 1
Translational Medical translational T Tr Tra Tran BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 ,,, 3 10 0 0 0 0 1
5 5 5 5 5 5 5 BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 9 6 no 0 10 0 0 0 0 1
Nottingham NIHR nottingham N No Not Nott BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 ,, 2 10 0 0 0 0 1
6 6 6 6 6 6 6 BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 9 6 no 0 10 0 0 0 0 1
School of school S Sc Sch Scho BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 6 ,,, 3 10 0 0 0 0 1
7 7 7 7 7 7 7 BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 9 6 no 0 10 0 0 0 0 1
School of school S Sc Sch Scho BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 6 ,,, 3 10 0 0 0 0 1
8 8 8 8 8 8 8 BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 9 6 no 0 10 0 0 0 0 1
University of university U Un Uni Univ BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 6 ,, 2 10 0 0 0 0 1
Contributors GN, contributors C Co Con Cont BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 6 ,,,,,,,,, 9 9 0 0 0 0 1
the study. the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 .,.,,, 6 9 0 0 0 0 1
TC, MWT, tc, T TC TC, TC, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 6 ,,,,,,. 7 9 0 0 0 0 1
manuscript. All manuscript. m ma man manu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 .. 2 9 0 0 0 0 1
corresponding author corresponding c co cor corr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 no 0 10 0 0 0 0 1
that no that t th tha that BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 6 .. 2 9 0 0 0 0 1
Funding This funding F Fu Fun Fund BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 7 no 0 10 0 0 0 0 1
Research (NIHR) research R Re Res Rese BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 9 7 ()(.). 6 5 0 0 0 0 1
Disclaimer The disclaimer D Di Dis Disc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 7 /. 2 10 0 0 0 0 1
Competing interests competing C Co Com Comp BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 7 (), 3 9 0 0 0 0 1
Springer (royalty), springer S Sp Spr Spri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 9 7 (),(),(), 9 9 0 0 0 0 1
Limbic (consulting) limbic L Li Lim Limb BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 7 ()() 4 9 0 0 0 0 1
to the to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 7 .,,, 4 9 0 0 0 0 1
AstraZeneca, Benevolent astrazeneca, A As Ast Astr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 7 ,,,,,, 6 8 0 0 0 0 1
Diagnostics, Servier diagnostics, D Di Dia Diag BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 7 ,,.. 4 8 0 0 0 0 1
University of university U Un Uni Univ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 7 ./ 2 9 0 0 0 0 1
Advisory board advisory A Ad Adv Advi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 7 ,,,,,, 6 9 0 0 0 0 1
Ono, Kite/Gilead, ono, O On Ono Ono, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 7 ,/,/,/ 6 9 0 0 0 0 1
from BeiGene from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 7 . 1 10 0 0 0 0 1
to declare. to t to to to BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 7 . 1 1 0 0 0 0 1
Patient consent patient P Pa Pat Pati BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 9 . 1 10 0 0 0 0 1
Ethics approval ethics E Et Eth Ethi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 9 no 0 10 0 0 0 0 1
Committee of committee C Co Com Comm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 9 (:,). 5 7 0 0 0 0 1
Provenance and provenance P Pr Pro Prov BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 9 ;. 2 10 0 0 0 0 1
Data availability data D Da Dat Data BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 9 no 0 9 0 0 0 0 1
publicly available. publicly p pu pub publ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 9 . 1 10 0 0 0 0 1
requirements. However, requirements. r re req requ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 9 .,. 3 8 0 0 0 0 1
Supplemental material supplemental S Su Sup Supp BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 9 (). 3 8 0 0 0 0 1
not been not n no not not BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 9 () 2 8 0 0 0 0 1
peer-reviewed. Any peer-reviewed. p pe pee peer BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 9 -. 2 8 0 0 0 0 1
of the of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 9 (). 3 8 0 0 0 0 1
responsibility arising responsibility r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 9 . 1 9 0 0 0 0 1
includes any includes i in inc incl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 9 , 1 9 0 0 0 0 1
of the of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 9 (,, 3 10 0 0 0 0 1
terminology, drug terminology, t te ter term BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 9 ,), 3 8 0 0 0 0 1
and/or omissions and/or a an and and/ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 9 /. 2 7 0 0 0 0 1
Open access open O Op Ope Open BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 10 no 0 8 0 1 0 0 1
Creative Commons creative C Cr Cre Crea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 10 .(.), 5 8 0 1 0 0 1
others to others o ot oth othe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 10 ,,, 3 9 0 1 0 0 1
purpose, provided purpose, p pu pur purp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 10 ,,, 3 10 0 1 0 0 1
and indication and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 10 .:://./ 7 9 0 1 0 0 1
licenses/by/4.0/. licenses/by/4.0/. licenses/by/4.0/. l li lic lice BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 10 //./. 5 2 0 1 0 0 1
RMD Open: rmd R RM RMD RMD BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 11 :./--.://... 12 10 0 0 0 0 0
Protected by protected P Pr Pro Prot BLOCKSTART PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 11 ,,,. 4 10 0 0 1 0 0
10 10 10 1 10 10 10 BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 0 no 0 10 0 1 0 0 0
Abhishek A, abhishek A Ab Abh Abhi BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,.;:.:./-- 10 10 0 1 1 0 0
RMD Open rmd R RM RMD RMD BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 no 0 10 0 1 0 0 0
RMD Open rmd R RM RMD RMD BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 no 0 10 0 1 0 0 0
RMD Open rmd R RM RMD RMD BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 no 0 10 0 1 0 0 0
ORCID iDs orcid O OR ORC ORCI BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 no 0 1 0 1 0 0 1
Abhishek Abhishek abhishek A Ab Abh Abhi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ://./--- 8 10 0 1 0 0 1
Tim Card tim T Ti Tim Tim BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 9 0 ://./--- 8 8 0 1 0 0 1
REFERENCES REFERENCES references R RE REF REFE BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 10 0 1 0 0 1
1 Ogdie 1 1 1 1 1 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 9 0 ,,. 3 9 0 0 0 0 1
arthritis. Rheumatology arthritis. a ar art arth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 .();:-. 7 6 0 0 0 0 1
2 Singh 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 9 0 .. 2 9 0 0 0 0 1
Clin North clin C Cl Cli Clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ;:-. 4 4 0 0 0 0 1
3 Ransford 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 9 0 ,.: 3 8 0 0 0 0 1
serious adverse serious s se ser seri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 - 1 9 0 0 0 0 1
adverse reaction adverse a ad adv adve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 9 0 0 0 0 1
Gut 2002;51:536-9. gut G Gu Gut Gut BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ;:-. 4 2 0 0 0 0 1
4 Farr 4 4 4 4 4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 9 0 ,,,. 4 9 0 0 0 0 1
arthritis: haematological arthritis: a ar art arth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 : 1 9 0 0 0 0 1
indices associated indices i in ind indi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 .;:-. 5 8 0 0 0 0 1
5 McConkey 5 5 5 5 5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 9 0 .. 2 9 0 0 0 0 1
Br J br B Br Br Br BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ;:-. 4 4 0 0 0 0 1
6 van 6 6 6 6 6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 9 0 ,,.- 4 8 0 0 0 0 1
and Side-effect and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 -. 2 9 0 0 0 0 1
Rheumatology 1995;XXXIV:40-2. rheumatology R Rh Rhe Rheu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ;:-. 4 4 0 0 0 0 1
7 de 7 7 7 7 7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 9 0 ,,,.. 5 10 0 0 0 0 1
relevant drug-induced relevant r re rel rele BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 -:- 3 9 0 0 0 0 1
study.BR. Br study.br. s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 ..;:-. 6 6 0 0 0 0 1
8 McConkey 8 8 8 8 8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 9 0 ,,,. 4 8 0 0 0 0 1
rheumatoid arthritis. rheumatoid r rh rhe rheu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 .;:-. 5 6 0 0 0 0 1
9 Farr 9 9 9 9 9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 9 0 ,,. 3 9 0 0 0 0 1
with inflammatory with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 9 0 0 0 0 1
1986;32 Suppl 1986;32 1 19 198 1986 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 0 ;:-. 4 3 0 0 0 0 1
10 Amos 10 1 10 10 10 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 0 ,,,. 4 9 0 0 0 0 1
arthritis: toxicity arthritis: a ar art arth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 :. 2 9 0 0 0 0 1
Med J med M Me Med Med BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ();:-. 6 5 0 0 0 0 1
11 MacGilchrist 11 1 11 11 11 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 0 ,.: 3 10 0 0 0 0 1
hypersensitivity response. hypersensitivity h hy hyp hype BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 .;:-. 5 7 0 0 0 0 1
12 Marabani 12 1 12 12 12 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 0 ,,,. 4 8 0 0 0 0 1
sulphasalazine treatment sulphasalazine s su sul sulp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 . 1 9 0 0 0 0 1
1989;48:505-7. 1989;48:505-7. 1989;48:505-7. 1 19 198 1989 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 0 ;:-. 4 2 0 0 0 0 1
13 Jobanputra 13 1 13 13 13 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 0 ,,,.. 5 9 0 0 0 0 1
associated with associated a as ass asso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 : 1 9 0 0 0 0 1
from a from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 .. 2 8 0 0 0 0 1
Musculoskelet Disord musculoskelet M Mu Mus Musc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ;:. 3 4 0 0 0 0 1
14 Keisu 14 1 14 14 14 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 0 ,. 2 9 0 0 0 0 1
Sweden 1972-1989. sweden S Sw Swe Swed BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 -.;:-. 6 7 0 0 0 0 1
15 Wiese 15 1 15 15 15 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 0 ,,',. 5 9 0 0 0 0 1
Nat2 and nat2 N Na Nat Nat2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 no 0 9 0 0 0 0 1
containing DMARD containing c co con cont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 7 0 0 0 0 1
Pharmacogenomics J pharmacogenomics P Ph Pha Phar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ;:-. 4 4 0 0 0 0 1
16 Grove 16 1 16 16 16 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 0 ,,,. 4 8 0 0 0 0 1
disease-modifying anti-rheumatic disease-modifying d di dis dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 --. 3 9 0 0 0 0 1
2001;94:309-19. 2001;94:309-19. 2001;94:309-19. 2 20 200 2001 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 0 ;:-. 4 2 0 0 0 0 1
17 Committee 17 1 17 17 17 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 0 ..[]. 5 9 0 0 0 0 1
and Pharmaceutical and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ;. 2 4 0 0 0 0 1
18 Ledingham 18 1 18 18 18 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 0 ,,,. 4 9 0 0 0 0 1
the prescription the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 -- 2 9 0 0 0 0 1
anti-rheumatic drugs. anti-rheumatic a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 -.();:-. 8 8 0 0 0 0 1
19 Singh 19 1 19 19 19 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 0 ,,,. 4 8 0 0 0 0 1
rheumatology guideline rheumatology r rh rhe rheu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 . 1 9 0 0 0 0 1
Arthritis Care arthritis A Ar Art Arth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ();:-. 6 5 0 0 0 0 1
20 Pfizer. 20 2 20 20 20 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 0 ..(). 5 9 0 0 0 0 1
2021. Available: 2021. 2 20 202 2021 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 0 .:://...//// 12 8 0 0 0 0 1
smpc#gref [Accessed smpc#gref s sm smp smpc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 #[]. 4 4 0 0 0 0 1
21 Herrett 21 2 21 21 21 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 0 ,,,. 4 8 0 0 0 0 1
profile: clinical profile: p pr pro prof BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 :(). 4 9 0 0 0 0 1
2015;44:827-36. 2015;44:827-36. 2015;44:827-36. 2 20 201 2015 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 0 ;:-. 4 2 0 0 0 0 1
22 Wolf 22 2 22 22 22 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 0 ,,,..: 6 9 0 0 0 0 1
clinical practice clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 (). 3 8 0 0 0 0 1
2019;48:1740-1740g. 2019;48:1740-1740g. 2019;48:1740-1740g. 2 20 201 2019 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 0 ;:-. 4 2 0 0 0 0 1
23 Abhishek 23 2 23 23 23 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 0 ,,-,. 5 9 0 0 0 0 1
getting less getting g ge get gett BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 -- 2 8 0 0 0 0 1
cohort study. cohort c co coh coho BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 .();:-. 7 7 0 0 0 0 1
24 Nakafero 24 2 24 24 24 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 0 ,,,. 4 8 0 0 0 0 1
monitoring for monitoring m mo mon moni BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 7 0 0 0 0 1
inflammatory diseases: inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 : 1 7 0 0 0 0 1
and validation and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 7 0 0 0 0 1
2023;381:e074678. 2023;381:e074678. 2023;381:e074678. 2 20 202 2023 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 0 ;:. 3 2 0 0 0 0 1
25 Nakafero 25 2 25 25 25 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 9 0 ,,,. 4 9 0 0 0 0 1
methotrexate or methotrexate m me met meth BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 , 1 9 0 0 0 0 1
liver enzyme liver l li liv live BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 ?. 2 8 0 0 0 0 1
(Oxford) 2021;60:5785-94. (oxford) ( (O (Ox (Oxf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 ();:-. 6 3 0 0 0 0 1
26 Khwaja 26 2 26 26 26 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 .. 2 9 0 0 0 0 1
Nephron Clin nephron N Ne Nep Neph BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 5 ;:-. 4 4 0 0 0 0 1
27 Chalasani 27 2 27 27 27 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 ,.- 3 8 0 0 0 0 1
induced liver induced i in ind indu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 .;:-. 5 7 0 0 0 0 1
28 Safy-Khan 28 2 28 28 28 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 -,,,. 5 8 0 0 0 0 1
negatively affects negatively n ne neg nega BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 no 0 8 0 0 0 0 1
arthritis in arthritis a ar art arth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 -, 2 8 0 0 0 0 1
prednisone use. prednisone p pr pre pred BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 .;:-. 5 5 0 0 0 0 1
29 Klotz 29 2 29 29 29 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 ., 2 9 0 0 0 0 1
and other and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 -. 2 8 0 0 0 0 1
1985;10:285-302. 1985;10:285-302. 1985;10:285-302. 1 19 198 1985 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 5 ;:-. 4 2 0 0 0 0 1
30 Meijer 30 3 30 30 30 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 ,,,. 4 9 0 0 0 0 1
therapy in therapy t th the ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 no 0 7 0 0 0 0 1
cell count cell c ce cel cell BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 :-. 3 8 0 0 0 0 1
2017;39:399-405. 2017;39:399-405. 2017;39:399-405. 2 20 201 2017 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 5 ;:-. 4 2 0 0 0 0 1
31 Dirven 31 3 31 31 31 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 ,,,. 4 8 0 0 0 0 1
transferase (ALT) transferase t tr tra tran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 () 2 8 0 0 0 0 1
treated with treated t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 -. 2 8 0 0 0 0 1
2013;32:585-90. 2013;32:585-90. 2013;32:585-90. 2 20 201 2013 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 5 ;:-. 4 2 0 0 0 0 1
32 Riley 32 3 32 32 32 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 ,,,. 4 8 0 0 0 0 1
size required size s si siz size BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 . 1 8 0 0 0 0 1
2020;368:m441. 2020;368:m441. 2020;368:m441. 2 20 202 2020 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 5 ;:. 3 1 0 0 0 0 1
33 Riley 33 3 33 33 33 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 ,,,. 4 8 0 0 0 0 1
for external for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 no 0 9 0 0 0 0 1
outcome. Stat outcome. o ou out outc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 .;:-. 5 4 0 0 0 0 1
34 Schafer 34 3 34 34 34 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 .:. 3 8 0 0 0 0 1
1999;8:3-15. 1999;8:3-15. 1999;8:3-15. 1 19 199 1999 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 5 ;:-. 4 1 0 0 0 0 1
35 Steyerberg 35 3 35 35 35 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 .: 2 8 0 0 0 0 1
to development, to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 ,,., 4 7 0 0 0 0 1
Springer International springer S Sp Spr Spri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 10 5 ;. 2 5 0 0 0 0 1
36 Royston 36 3 36 36 36 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 ,. 2 8 0 0 0 0 1
model: principles model: m mo mod mode BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 :. 2 6 0 0 0 0 1
2013;13:33. 2013;13:33. 2013;13:33. 2 20 201 2013 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 5 ;:. 3 1 0 0 0 0 1
37 Cox 37 3 37 37 37 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 ..;:. 5 6 0 0 0 0 1
38 Moons 38 3 38 38 38 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 ,,,. 4 8 0 0 0 0 1
of a of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 no 0 8 0 0 0 0 1
diagnosis (TRIPOD): diagnosis d di dia diag BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 ():. 4 8 0 0 0 0 1
2015;162:W1-73. 2015;162:W1-73. 2015;162:w1-73. 2 20 201 2015 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 5 ;:-. 4 2 0 0 0 0 1
39 Ricart 39 3 39 39 39 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 ,,,.- 5 9 0 0 0 0 1
genotypes do genotypes g ge gen geno BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 no 0 8 0 0 0 0 1
mesalamine and mesalamine m me mes mesa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 . 1 9 0 0 0 0 1
Gastroenterol 2002;97:1763-8. gastroenterol G Ga Gas Gast BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 5 ;:-. 4 3 0 0 0 0 1
40 Mielnik 40 4 40 40 40 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 ,,,. 4 8 0 0 0 0 1
sulfasalazine, leflunomide sulfasalazine, s su sul sulf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 , 1 7 0 0 0 0 1
events in events e ev eve even BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 10 5 -(-). 5 8 0 0 0 0 1
2023;7:rkad053. 2023;7:rkad053. 2023;7:rkad053. 2 20 202 2023 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 5 ;:. 3 2 0 0 0 0 1
41 Mori 41 4 41 41 41 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 ,,,.-- 6 9 0 0 0 0 1
pattern in pattern p pa pat patt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 no 0 9 0 0 0 0 1
Transaminitis during transaminitis T Tr Tra Tran BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 5 -. 2 8 0 0 0 0 1
2018;13:e0203084. 2018;13:e0203084. 2018;13:e0203084. 2 20 201 2018 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 5 ;:. 3 2 0 0 0 0 1
42 Nakafero 42 4 42 42 42 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 ,,,. 4 9 0 0 0 0 1
of a of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 no 0 8 0 0 0 0 1
blood tests blood b bl blo bloo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 -: 2 8 0 0 0 0 1
from the from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 . 1 8 0 0 0 0 1
Rheumatology (Oxford) rheumatology R Rh Rhe Rheu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 5 ();:-. 6 5 0 0 0 0 1
43 Cavalli 43 4 43 43 43 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 ,,,.- 5 7 0 0 0 0 1
association study association a as ass asso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 no 0 8 0 0 0 0 1
of rheumatoid of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 -. 2 8 0 0 0 0 1
Pharmacogenomics 2022;23:813-20. pharmacogenomics P Ph Pha Phar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 5 ;:-. 4 4 0 0 0 0 1
44 Sherbini 44 4 44 44 44 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 ,,,. 4 8 0 0 0 0 1
of methotrexate-related of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 - 1 8 0 0 0 0 1
rheumatoid arthritis: rheumatoid r rh rhe rheu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 :. 2 7 0 0 0 0 1
Rheumatology (Oxford) rheumatology R Rh Rhe Rheu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 5 ();:-. 6 5 0 0 0 0 1
45 Suzuki 45 4 45 45 45 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 ,,,.- 5 9 0 0 0 0 1
of high-dose of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 -(/) 4 8 0 0 0 0 1
rheumatoid arthritis: rheumatoid r rh rhe rheu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 :- 2 9 0 0 0 0 1
duration of duration d du dur dura BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 .;:-. 5 8 0 0 0 0 1
46 Verstappen 46 4 46 46 46 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 ,,,. 4 8 0 0 0 0 1
and factors and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 no 0 9 0 0 0 0 1
arthritis treated arthritis a ar art arth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 : 1 8 0 0 0 0 1
CAMERA study. camera C CA CAM CAME BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 10 5 .;:-. 5 5 0 0 0 0 1
47 Schmajuk 47 4 47 47 47 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 ,,,. 4 10 0 0 0 0 1
elevated transaminases elevated e el ele elev BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 no 0 8 0 0 0 0 1
health record. health h he hea heal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 10 5 .();:-. 7 8 0 0 0 0 1
48 Hastings 48 4 48 48 48 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 10 5 ,,,. 4 9 0 0 0 0 1
anti-tumor necrosis anti-tumor a an ant anti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 -.() 4 8 0 0 0 0 1
2010;62:764-9. 2010;62:764-9. 2010;62:764-9. 2 20 201 2010 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 5 ;:-. 4 1 0 0 0 0 1
RMD Open: rmd R RM RMD RMD BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 11 11 :./--.://... 12 10 0 0 0 0 1
Protected by protected P Pr Pro Prot BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 11 ,,,. 4 10 0 0 1 0 1

